8-K: Vicarious Surgical Faces NYSE Delisting Threat, Addresses Material Weaknesses, and Appoints New Auditor

Vicarious Surgical Inc. received NYSE acceptance for its plan to regain compliance with listing standards after falling below market capitalization and stockholders' equity thresholds, while also dismissing Deloitte & Touche LLP and engaging Cherry Bekaert LLP as its new independent auditor amidst ongoing material weaknesses in internal controls.

Summary

• Vicarious Surgical Inc. (RBOT) received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards due to its average global market capitalization and stockholders' equity both being less than $50 million over a 30-trading-day period.
• The company submitted a compliance plan, which the NYSE accepted on July 8, 2025, granting an 18-month cure period to regain compliance.
• During the cure period, the company's Class A common stock will continue to be listed and traded on the NYSE, but its trading symbol will include a ".BC" designation to indicate its below-criteria status.
• On July 7, 2025, the company dismissed Deloitte & Touche LLP as its independent registered public accounting firm, a decision approved by the Audit Committee.
• Deloitte's audit report for the years ended December 31, 2024 and 2023 included an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company reported material weaknesses in internal control over financial reporting for the fiscal year ended December 31, 2024, and the quarter ended March 31, 2025, related to insufficient business processes, personnel, and controls for public company accounting, including issues with segregation of duties, IT controls, and risk assessment.
• Also on July 7, 2025, the Audit Committee approved the engagement of Cherry Bekaert LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 3

Explanation: The company faces significant challenges, including a delisting threat and material weaknesses in internal controls, compounded by a going concern explanatory paragraph from its former auditor. While the NYSE accepted the compliance plan, the underlying issues are severe and indicate financial distress and operational deficiencies.

Positives

• NYSE accepted the company's compliance plan, providing an 18-month cure period to regain listing compliance.
• The company's Class A common stock will continue to be listed and traded on the NYSE during the cure period.
• The noncompliance with NYSE listing standards does not affect ongoing business operations or SEC reporting requirements.
• No disagreements were reported with Deloitte & Touche LLP on accounting principles, financial statement disclosure, or auditing scope/procedure.

Negatives

• The company is not in compliance with NYSE's Minimum Market Capitalization Standard, with both its average global market capitalization and stockholders' equity falling below $50 million.
• Deloitte's audit report included an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company has disclosed material weaknesses in its internal control over financial reporting for the fiscal year ended December 31, 2024, and the quarter ended March 31, 2025.
• Material weaknesses include lacking necessary business processes, personnel, and internal controls for public company accounting, improper segregation of duties, issues with IT controls, and ineffective risk assessment.
• The company's Class A common stock trading symbol will have a ".BC" designation, indicating its below-criteria status.

Risks

• Risk of delisting from the NYSE if the company fails to comply with the accepted Compliance Plan or does not meet the Minimum Market Capitalization Standard by the end of the 18-month cure period.
• Ongoing material weaknesses in internal control over financial reporting could lead to inaccuracies in financial statements and impact investor confidence.
• The explanatory paragraph regarding the company's ability to continue as a going concern indicates significant financial uncertainty.

Future Outlook

The company is actively considering all available options to regain compliance with NYSE's continued listing standards within the 18-month cure period.

Management Comments

• The company is considering all available options to regain compliance with NYSEs continued listing standards.

Industry Context

This announcement primarily reflects company-specific challenges related to financial performance and internal controls, rather than broader industry trends. The medical robotics and surgical technology sector, in which Vicarious Surgical operates, typically requires significant capital investment and faces intense competition and regulatory scrutiny, which can exacerbate financial pressures for companies not meeting growth or profitability targets.

Comparison to Industry Standards

• The company's failure to meet the NYSE's minimum market capitalization and stockholders' equity standards of $50 million each indicates a significant underperformance relative to the general expectations for publicly traded companies on major exchanges.
• While specific comparable companies are not named in the document, successful peers in the surgical robotics space, such as Intuitive Surgical (ISRG) or Stryker (SYK) (which has a robotics division), typically maintain market capitalizations in the tens or hundreds of billions and robust stockholders' equity, demonstrating strong financial health and investor confidence.
• The material weaknesses in internal controls also suggest a deficiency in corporate governance and operational maturity compared to established industry leaders who adhere to stringent financial reporting and control frameworks.

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased risk of delisting, potential loss of liquidity if delisted, and a negative perception due to the ".BC" stock symbol designation. The going concern explanatory paragraph also raises concerns about the company's long-term viability.
• Investors: Will likely view the company with increased caution due to the delisting threat, financial instability indicators, and internal control deficiencies.
• Management/Employees: Face pressure to improve financial performance and remediate internal control weaknesses to ensure continued listing and business operations.

Next Steps

• The company must take definitive actions to regain compliance with the NYSE's Minimum Market Capitalization Standard within the 18-month cure period (by October 10, 2026).
• The NYSE will review the company on a quarterly basis to confirm compliance with the accepted plan.
• Cherry Bekaert LLP will audit the company's financial statements for the fiscal year ending December 31, 2025.
• The company needs to address and remediate the disclosed material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Keywords

Vicarious Surgical Inc., RBOT, NYSE, Delisting, Compliance Plan, Market Capitalization, Stockholders Equity, Auditor Change, Deloitte & Touche LLP, Cherry Bekaert LLP, Material Weaknesses, Internal Control Over Financial Reporting, Going Concern, SEC Filing, 8-K